EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

Statin therapy and cardiovascular protection in type 2 diabetes: The role of baseline LDL-Cholesterol levels. A systematic review and meta-analysis of observational studies

Negin Soroush, Mitra Nekouei Shahraki, Soroush Mohammadi Jouabadi, Masoud Amiri, Elif Aribas, Bruno H Stricker, Fariba Ahmadizar

Nutrition, Metabolism and Cardiovascular Diseases · 2024

DOI: 10.1016/j.numecd.2024.04.015 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Nutrition, Metabolism and Cardiovascular Diseases, 2024. Verfasst von Negin Soroush und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Cholesterol, LDL, Cardiovascular Diseases. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AIM: The guidelines recommend statins to prevent cardiovascular events in patients with type 2 diabetes (T2D) however, the importance of baseline LDL-Cholesterol (LDL-C) levels remains controversial. This study aimed to determine the association of statin use in T2D patients with major adverse cardiovascular events (MACE) and all-cause mortality and whether this association differs by baseline LDL-C levels. DATA SYNTHESIS: Medline, Embase, and Web of Science were systematically searched from inception until January 2022. Observational studies in patients with T2D comparing statin users vs non-users, with reports of the baseline LDL-C levels, were included. Random-effects meta-analysis and meta-regression were performed to estimate the overall effect on the risk of all-cause mortality and MACE (a composite of myocardial infarction, heart failure, stroke, and revascularization events) and the modification in the association by baseline LDL-C levels. We categorized studies according to their baseline LDL-C levels into 1) 130 mg/dl (3.37 mmol/l) categories. A total of 9 cohort studies (n = 403,411 individuals) fulfilled our criteria. The follow-up duration ranged from 1.7 to 8 years. The overall combined estimate showed that statin therapy was associated with a significantly lower risk of MACE (Hazard Ratio (HR): 0.70 [95% CI 0.59 to 0.83], Absolute risk reduction percentage (ARR%): 3.19% [95%CI 0.88 to 5.50%) and all-cause mortality (HR: 0.60 [95% CI 0.46 to 0.79], ARR%: 5.23% [95% CI 2.18 to 8.28%), but varied, albeit not statistically significant, by baseline LDL-C levels. Studies with baseline LDL-C levels higher than 130 mg/dl had the greatest reduction of MACE (HR: 0.58 [95% CI 0.37 to 0.90]) and all-cause mortality risk (HR: 0.51 [95% CI [ 0.29 to 0.90]). The HRs of MACE in studies with LDL-C levels of 100-130 mg/dl and

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Hydroxymethylglutaryl-CoA Reductase InhibitorsCholesterol, LDLCardiovascular DiseasesObservational Studies as TopicBiomarkersHumansRisk AssessmentFemaleMaleTreatment OutcomeMiddle AgedAgedDyslipidemiasProtective FactorsTime Factors

Stichwörter der Autor:innen

All-cause mortalityLDL-CholesterolMajor adverse cardiovascular eventsStatinType 2 diabetes

Substanzen

Hydroxymethylglutaryl-CoA Reductase InhibitorsCholesterol, LDLBiomarkers

Autor:innen und Institutionen

  • Department of Epidemiology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands.
  • Department of Epidemiology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands; Pharmacology and Vascular Medicine Center, Department of Internal Medicine, Erasmus MC, University Medical Center, Rotterdam…
  • Department of Epidemiology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands; Department of Data Science and Biostatistics, Julius Global Health, University Medical Center Utrecht, Utrecht, the Netherla…

Zitieren

APA

Soroush, N., Nekouei Shahraki, M., Mohammadi Jouabadi, S., Amiri, M., Aribas, E., Stricker, B. H., & Ahmadizar, F. (2024). Statin therapy and cardiovascular protection in type 2 diabetes: The role of baseline LDL-Cholesterol levels. A systematic review and meta-analysis of observational studies. Nutrition, Metabolism and Cardiovascular Diseases. https://doi.org/10.1016/j.numecd.2024.04.015

Vancouver

Soroush N, Nekouei Shahraki M, Mohammadi Jouabadi S, Amiri M, Aribas E, Stricker BH, et al. Statin therapy and cardiovascular protection in type 2 diabetes: The role of baseline LDL-Cholesterol levels. A systematic review and meta-analysis of observational studies. Nutrition, Metabolism and Cardiovascular Diseases. 2024. doi:10.1016/j.numecd.2024.04.015

BibTeX
@article{Soroush2024,
  author = {Soroush, Negin and Nekouei Shahraki, Mitra and Mohammadi Jouabadi, Soroush and Amiri, Masoud and Aribas, Elif and Stricker, Bruno H and Ahmadizar, Fariba},
  title = {Statin therapy and cardiovascular protection in type 2 diabetes: The role of baseline LDL-Cholesterol levels. A systematic review and meta-analysis of observational studies},
  journal = {Nutrition, Metabolism and Cardiovascular Diseases},
  year = {2024},
  doi = {10.1016/j.numecd.2024.04.015}
}
Kostenlos starten →